Free Trial

bioMérieux S.A. (OTCMKTS:BMXMF) Short Interest Up 6.6% in November

bioMérieux logo with Medical background

bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 139,000 shares, an increase of 6.6% from the November 15th total of 130,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 1,390.0 days.

Wall Street Analyst Weigh In

Separately, UBS Group upgraded shares of bioMérieux to a "strong-buy" rating in a research note on Thursday, August 22nd.

Get Our Latest Report on BMXMF

bioMérieux Price Performance

Shares of BMXMF stock traded up $0.93 on Friday, hitting $107.03. The stock had a trading volume of 140 shares, compared to its average volume of 337. The stock's 50 day moving average is $108.32 and its 200-day moving average is $107.61. bioMérieux has a 52-week low of $93.50 and a 52-week high of $122.52.

About bioMérieux

(Get Free Report)

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.

Featured Articles

Should you invest $1,000 in bioMérieux right now?

Before you consider bioMérieux, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMérieux wasn't on the list.

While bioMérieux currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines